Brief: FDA Approves Belzutifan With Pembrolizumab For Adjuvant Treatment Of Renal Cell Carcinoma
12/06/2026 18:22
BRIEF-FDA Approves Belzutifan With Pembrolizumab For Adjuvant Treatment Of Renal Cell Carcinoma June 12 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN WITH PEMBROLIZUMAB FOR ADJUVANT TREATMENT OF RENAL CELL CARCINOMA
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials